|
Acusphere, Inc. - Comparative Business Analysis Snapshot
Business Description
Acusphere, Inc.. The Group's principal activity is to develop new drugs and improved formulations of existing drugs using proprietary porous microparticle technology. It focused on developing proprietary drugs, including improved safety and efficacy, increased patient compliance, greater ease of use, expanded indications or reduced cost. It develops proprietary drug that offers benefits such as improved safety and efficacy, increased patient compliance and greater ease of use. Its products are in clinical development and are designed to address clinical needs within cardiology, oncology and asthma. It has initially applied its technology in its research and development efforts in areas of AI-700, Intravenous Delivery of Gas for Ultrasound Contrast; AI-850, first clinical-stage product candidate from its Hydrophobic Drug Delivery System, and AI-128, first clinical-stage product candidate from its Pulmonary Drug Delivery System. The Group is a development stage company.
Competitor Analysis
This analysis compares Acusphere, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
